KunchokAAksamitAJDavisJM, et al.Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol2020; 77: 937–946. doi: 10.1001/jamaneurol.2020.1162. PMID: 32421186; PMCID: PMC7235930.
2.
KaltsonoudisEZikouAKVoulgariPV, et al.Neurological adverse events in patients receiving anti-TNF therapy : a prospective imaging and electrophysiological study. Arthritis Res Ther2014; 16: R125.
3.
UchioNYashitaDHaoA, et al.Intravenous immunoglobulin in the treatment of Adalimumab-associated optic neuritis. Intern Med2022; 61: 429–432. doi: 10.2169/internalmedicine.7599-21. Epub 2021 Aug 6. PMID: 34373376; PMCID: PMC8866781.
4.
Pihl-JensenGSchmidtMFFrederiksenJL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: a review. Clin Neurophysiol2017; 128: 1234–1245. doi: 10.1016/j.clinph.2017.03.047. Epub 2017 Apr 11. PMID: 28531809.
5.
DahanayakePDassanayakeTLPathirageM, et al.The effect of optic neuritis treatment trial (ONTT) combined corticosteroid regimen on pattern reversal visual evoked potentials: a prospective follow-up study. BMC Ophthalmol2021; 21: 324. doi: 10.1186/s12886-02102086-z. PMID: 34488685; PMCID: PMC8422770.
